Analyst Price Targets — MGX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 21, 2024 6:16 am | Mitchell Kapoor | H.C. Wainwright | $7.00 | $3.30 | TheFly | Metagenomi price target lowered to $7 from $10 at H.C. Wainwright |
| March 28, 2024 7:49 am | Maury Raycrof | Jefferies | $22.00 | $11.09 | StreetInsider | Metagenomi Inc (MGX) PT Lowered to $22 at Jefferies |
Latest News for MGX
EMERYVILLE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced that Jian Irish, Ph.D.
Shareholders are urged to contact the firm immediately at no cost or obligation, as there may be limited time to enforce your rights. We would handle the matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
MGX Resources Limited (MTGRY) Q4 2026 Earnings Call Prepared Remarks Transcript
Metagenomi Therapeutics (MGX) came out with a quarterly loss of $0.73 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to a loss of $0.54 per share a year ago.
MGX Resources Limited (MTGRY) Q4 2026 Earnings Call Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for MGX.
U.S. House Trading
No House trades found for MGX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.